CA - A Cancer Journal for Clinicians Q1 Unclaimed

Wiley-Blackwell United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

CA: A Cancer Journal for Clinicians is a peer-reviewed journal published for the American Cancer Society by John Wiley & Sons, Inc. CA publishes comprehensive review articles of a multidisciplinary nature, which take into account the journal’s diverse readership of primary care physicians; medical, surgical, and radiation oncologists; nurses; and other health care and public health professionals. Articles published in CA provide up-to-date information on all aspects of cancer prevention, early detection, treatment of all forms, palliation, advocacy, quality of life, and more. It has an SJR impact factor of 62,937.

CA - A Cancer Journal for Clinicians focuses its scope in these topics and keywords: cancer, management, diagnosis, statistics, pharmacogenetics, peripheral, prognosisexpectant, prostate, pharmacogenomics, reduce, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2500 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

CA - A Cancer Journal for Clinicians

62,937

SJR Impact factor

168

H Index

47

Total Docs (Last Year)

119

Total Docs (3 years)

3452

Total Refs

15499

Total Cites (3 years)

80

Citable Docs (3 years)

126,34

Cites/Doc (2 years)

73,45

Ref/Doc

Aims and Scope


cancer, management, diagnosis, statistics, pharmacogenetics, peripheral, prognosisexpectant, prostate, pharmacogenomics, reduce, skin, stage, survivorship, treatment, tumor, understanding, men, rate, patientscancer, nonmelanoma, neurotoxicity, anticancer, cancers, chemotherapyinduced, chronic, critical, early, found, imatinib, leukemianicotinamide, markers, myelogenous, myeloproliferative, neoplasmsdiscontinuation,



Best articles by citations

The Mammographic Screening Trials: Commentary on the Recent Work by Olsen and Gotzsche

View more

Viewing the: Journal of the national cancer institute

View more

Prostate cancer

View more

Reviewer Acknowledgment 2007

View more

Reviewer Acknowledgment 2011

View more

Editorial: The environmental time bomb ...that never went off

View more

Reviewer acknowledgment 2014

View more

Daily aspirin may reduce mortality from prostate cancer with risk of high recurrence

View more

Few physicians prescribe 5-alpha reductase inhibitors for prostate cancer prevention

View more

Introdiction to "evaluation of periodic breast cancer screening with mammography mathodology and early obstrvation" by shapiro, atrax, and vent

View more

Enhancing global access to cancer medicines

View more

Feedback

View more
SHOW MORE ARTICLES

Commentary on "European Consensus Statement on Lung Cancer"

View more

Increased radiation intensity found to be safe for the treatment of prostate cancer

View more

Estrogens and increased endometrial cancer: Fact or artifact?

View more

Consensus statement from the American Cancer Society Workshop on neuroblastoma screening: Do benifit from mass screening for neuroblastoma?

View more

Patients with nonovarian peritoneal carcinomatosis achieve long-term survival

View more

Acupressure and Acupuncture for Side Effects of Radiotherapy

View more

The Current Outbreak of Kaposi's Sarcoma and Opportunistic Infections

View more

Elimination of cancer disparities via organizational transformation and community-driven approaches

View more

American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer

View more

American Cancer Society guidelines for the early detection of breast cancer: update 1997

View more

American Cancer Society guidelines on screening for breast cancer: An overview

View more

The impact of breast cancer on sexuality, body image, and intimate relationships

View more

Comments

No comments ... Be the first to comment!

FAQS